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Abstract
Mechanisms governing the inflammatory response during sepsis have been shown to be complex, involving cross-talk
between diverse signaling pathways. Current knowledge regarding the mechanisms underlying sepsis provides an
incomplete picture of the syndrome, justifying additional efforts to understand this condition. Microarray-based expression
profiling is a powerful approach for the investigation of complex clinical conditions such as sepsis. In this study, we
investigate whole-genome expression profiles in mononuclear cells from survivors (n = 5) and non-survivors (n = 5) of sepsis.
To circumvent the heterogeneity of septic patients, only patients admitted with sepsis caused by community-acquired
pneumonia were included. Blood samples were collected at the time of sepsis diagnosis and seven days later to evaluate
the role of biological processes or genes possibly involved in patient recovery. Principal Components Analysis (PCA)
profiling discriminated between patients with early sepsis and healthy individuals. Genes with differential expression were
grouped according to Gene Ontology, and most genes related to immune defense were up-regulated in septic patients.
Additionally, PCA in the early stage was able to distinguish survivors from non-survivors. Differences in oxidative
phosphorylation seem to be associated with clinical outcome because significant differences in the expression profile of
genes related to mitochondrial electron transport chain (ETC) I–V were observed between survivors and non-survivors at the
time of patient enrollment. Global gene expression profiles after seven days of sepsis progression seem to reproduce, to a
certain extent, patterns collected at the time of diagnosis. Gene expression profiles comparing admission and follow-up
samples differed between survivors and non-survivors, with decreased expression of genes related to immune functions in
non-survivors. In conclusion, genes related to host defense and inflammatory response ontology were up-regulated during
sepsis, consistent with the need for a host response to infection, and the sustainability of their expression in follow-up
samples was associated with outcomes.
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Introduction
Sepsis has been defined as a systemic inflammatory response
secondary to a proven or suspected infection [1]. Mechanisms
governing this inflammatory response have been shown to be
complex and dynamic [2]. A compensatory anti-inflammatory
response (CARS) also takes place during sepsis, and the balance
between both responses may underlie the pathophysiology of the
syndrome [3]. Cell functional studies have underscored that the
state of inflammatory response in sepsis is followed by a state of
hypo-responsiveness or immunosuppression, which makes patients
susceptible to late-stage infections with increased lethality [4,5].
Microarray-based expression profiling is a powerful approach
for the investigation of complex clinical conditions: the analysis of
gene transcription at the genome level in sepsis potentially avoids
results derived from biased assumptions. The application of
microarray technology for biomarker discovery as well as for the
comprehension of underlying mechanisms in sepsis and septic
shock has been recently reviewed in the literature [6]. Two main
approaches are readily distinguishable: experimental studies
including endotoxemia studies in human volunteers [7,8] and
sepsis in experimental animals [9], and microarray-based studies
targeting patients with sepsis or septic shock [10–12]. Despite the
clear advantages of the controlled and reproducible first approach,
which allows the investigator to overcome sample complexity,
models are limited and cannot fully represent the inherent
heterogeneity of clinical sepsis.
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Patient-focused studies have produced findings on the hyperac-
tivity of pathogen recognition receptors and signaling cascade
pathways in sepsis, corroborating classical paradigms in sepsis
research, but have not reached consensus regarding the two-phase
model of an initial hyper-inflammatory phase followed by a
compensatory anti-inflammatory phase [13,14]. An alternate
paradigm suggests that adaptive immune dysfunction is an early
feature in sepsis, as has been reported in studies addressing the
gene expression profiles of peripheral blood leukocytes after
endotoxin challenge in humans [8] and mononuclear cell-specific
gene expression profiles [12,15].
Studies evaluating gene expression in LPS-induced tolerance
models have supported a distinct scenario in which LPS-tolerant
cells presenting tolerant (T) and non-tolerant (NT) genes are
driven to control inflammation, yet preserving important func-
tions, such as antimicrobial activity [16,17].
Thus, the current state of knowledge on mechanisms underlying
sepsis is far from providing a conclusive picture of the syndrome,
justifying additional efforts to characterize the condition. In this
study, we investigate whole-genome gene expression profiles of
mononuclear cells from survivors and non-survivors of sepsis.
Blood samples were collected at the time of sepsis diagnosis and
seven days later, allowing us to evaluate the role of biological
processes or genes that may be involved in patient recovery.
Aiming to at least partially circumvent the heterogeneity of septic
patient populations, we included only patients admitted with sepsis
caused by community-acquired pneumonia.
Materials and Methods
Patients and Healthy Volunteers
A cohort of septic patients was enrolled from the Intensive Care
Units of three general hospitals located in Sa˜o Paulo, Brazil. This
study was approved by the ethics committees of the participating
hospitals, Sa˜o Paulo Hospital (Study number 1477/06), Albert
Einstein Hospital (Study number 07/549) and Sı´rio Libaneˆs
Hospital (Study number 2006/27). Written informed consent was
obtained from all participants or, when necessary, from relatives
before enrollment in the study protocol. Patients older than 18
years were enrolled within 48 hours of the first occurrence of
organ dysfunction indicative of severe sepsis or septic shock.
Exclusion criteria included patients under 18 years old, patients
with immunosuppressive therapy, AIDS or end stage chronic
illness, or who had been submitted to experimental therapy. Ten
septic patients with community-acquired pneumonia as the
primary source of infection were selected for this study, five of
whom survived and five of whom died during hospitalization.
Three healthy volunteers were enrolled as controls.
Blood samples
Fifty milliliters of blood were collected in sodium heparin-
treated tubes (BD Biosciences, Franklin Lakes, NJ, USA) from
healthy volunteers and septic patients. Samples from septic
patients were collected at two time points: D0 (within 48 hours
of the first occurrence of organ dysfunction indicative of severe
sepsis or septic shock) and D7 (seven days after the first sample was
collected). Peripheral blood mononuclear cells were obtained using
the Ficoll gradient method (Ficoll-Paque PLUS; GE Healthcare
Bio-Sciences AB, Uppsala, Sweden). Cells were frozen in fetal
bovine serum (Invitrogen-Gibco, Gaithersburg, MD, USA) with
10% dimethyl sulfoxide (Calbiochem, La Jolla, CA, USA) and
stored in liquid nitrogen until use. The standard cell concentration
was 16107 cells/mL.
RNA extraction
Total RNA was isolated from peripheral mononuclear cells
using an illustra RNAspin Mini Kit (GE Healthcare Bio-Sciences
AB). The quality and concentration of the RNA was determined
using an RNA Nano Chip Kit and a 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, CA, USA).
Microarray analysis
Microarray analysis was performed using Agilent Whole
Human Genome Microarray 4644K arrays and the One Color
Quick Amp Labeling Kit (Agilent Technologies). Hybridization
and washing were performed according to the manufacturer’s
protocols (Agilent Technologies). The arrays were scanned using a
GenePix 4000B Scanner (Axon) and analyzed using the Agilent
Feature extraction software (version 9.5). The quality of the
microarray data was assessed using the standard Agilent controls
to verify expected quality control criteria. The gProcessedSignal
from each array was loaded into the Partek Genomics Suite (v6.6),
normalized between arrays using quantile normalization, and log
transformed. We used Principal Components Analysis (PCA) as an
exploratory tool to identify major effects influencing data. For
subsequent statistical analysis we used the ANOVA implementa-
tion of Partek. The ANOVA model was defined by the
experimental design and included variations due to volunteer
group (sepsis, control), day of sepsis sample collection (D0, D7) and
survival status (survivor, non-survivor). Patterns related to biolog-
ical function were then assessed using Gene Ontology (GO) term
enrichment analysis and KEGG pathway mapping through
DAVID Bioinformatics Resources 6.7 (http://david.abcc.ncifcrf.
gov). The raw microarray data can be assessed at Gene Expression
Omnibus (GEO accession GSE48080). The cut-off for differential
expression took into consideration the characteristics of each
experiment. These data are reported in the results section.
Results
Patients and healthy volunteers
All patients included in the study were males with community
acquired pneumonia (CAP) who either succumbed to or survived
their sepsis episode, with age ranging from 25 to 92 years. Five
patients were admitted with severe sepsis and five with septic
shock. APACHEII scores ranged from 7 to 23, and SOFA scores
ranged from 2 to 11 at enrollment (Table 1). Healthy controls, two
females and one male, were 36, 58 and 84 years old.
Global gene expression analysis characterizes septic
patients
Gene expression profiling by means of DNA microarrays was
used to assess the behavior of biological processes characterizing
septic patients. We performed principal components analysis and
GO and KEGG term enrichment analyses to evaluate global
patterns of expression between groups of individuals. The first
analysis considered all septic patients at the moment of sepsis
diagnosis (D0) compared to healthy individuals. Figure 1 depicts
global differences in gene expression, as identified by PCA. Septic
patients appear to cluster separately from healthy individuals
(Figure 1A), and two distinct groups based on outcome are also
apparent (Figure 1B).
One hundred and fifty one genes presented at least a 1.7-fold-
change in gene expression between septic patients (D0) and
healthy individuals: 104 were up-regulated and 49 were down-
regulated in septic patients (Table S1, p#0.05). To identify
biological processes potentially connected with the septic pheno-
type, these genes were grouped by Gene Ontology (Table 2).
Gene Expression and Outcomes from Septic Patients
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Notably, most genes related to immune defense were up-regulated
in septic patients.
Oxidative phosphorylation in early sepsis might be
associated with patient outcome
When comparing data from survivors and non-survivors at the
time of diagnosis (D0), focusing on genes with at least a 1.7-fold
change and p-value ,0.05, we observed no consistent dysregu-
lation of biological processes (Table S2). However, we considered
all genes that presented a significant variation based on the FDR
corrected p-value, including some genes with less than a 1.7-fold-
change, and identified 28 genes implicated in energy metabolism.
The genes - UQCRC2, NDUFB5, NDUFB6, COX10, ATP5B,
COX7C, COX5A, COX5B, NDUFB1, ATP5J, NDUFA4,
NDUFA5, COX7A2, NDUFA8, NDUFA9, NDUFA7, COX4I2,
NDUFC2, ATP5F1, NDUFA10, PPA2, NDUFA11, PPA1,
ATP6V1C1, ATP6V1E1, ATP6V1E2, COX6A2, and ATP5C1
- exhibited mild but consistent variation in expression between the
two groups.
Table 1. Demographic data and outcomes from septic patients included in this study.
Patients Age (years) Status at admission Vasopressors Apache II SOFA Outcome
P107 82 Septic shock Yes 23 6 Alive
P140 47 Severe sepsis Yes 16 11 Alive
P143 71 Severe sepsis No 10 3 Alive
P146 57 Septic shock Yes 14 10 Dead
P217 83 Severe sepsis No 14 4 Dead
P227 92 Septic shock Yes 12 10 Dead
P229 32 Severe sepsis No 7 7 Alive
P239 84 Septic shock Yes 19 9 Dead
P254 58 Septic shock Yes 23 9 Dead
P260 25 Severe sepsis No 15 2 Alive
doi:10.1371/journal.pone.0091886.t001
Figure 1. Global gene expression of healthy controls and septic patients. Unsupervised classification by principal components analysis of
septic patients and controls. Principal components analysis (PCA) was used to classify 10 patients and 3 controls based on global gene expression. A:
Septic patients cluster separately from healthy individuals at D0 (time of sepsis diagnosis). B: Global gene expression distinguishes survivors from
non-survivors at D0. Numbers refers to the identification of patients and healthy volunteers.
doi:10.1371/journal.pone.0091886.g001
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Sepsis progression and patient outcome
With the aim of analyzing biological processes associated with
sepsis progression, blood samples were collected 7 days after
diagnosis (D7). A comparison of gene expression profiles on D0
and D7 reveals that patterns observed in PCA on D0 persist on
D7, as depicted in Figure 2.
When comparing samples from survivors on D0 and D7 time
points, although we observed differences in gene expression
between the two groups, such differences were not robust enough
to generate an acceptable p value (Table S3) and we were not able
to identify a clear deregulation in cellular processes. For non-
survivors, despite the fact that gene expression differences were not
robust either (Table S4) through the analysis of these differences a
broader induction of genes involved in immune response was seen
on D0 when compared with D7 (Table 3).
Additionally we compared the D7 time point between survivor
and non-survivors. Functional clustering of genes up-regulated on
D7 in survivors compared with non-survivors included immune
response (GO:0006955), defense response (GO:0006952), cell
activation (GO:0001775) and antigen processing and presentation
of peptide or polysaccharide antigen via MHC class II
(GO:0002504) (Table 4). Global results comparing survivors and
non-survivors on D7 are reported in Table S5.
Discussion
The cohort of septic patients included in this study is
representative of patients admitted in Intensive Care Units with
CAP as a source of primary infection. The majority of patients
were elderly, half of them in septic shock. Most of the patients with
septic shock did not survive, while patients diagnosed with severe
sepsis survived and were discharged. Two exceptions were patient
P107, a septic shock patient who survived, and P217, a severe
septic patient who died.
Table 2. Gene Ontology (GO) terms significantly represented among genes differentially expressed between healthy individuals
and patients at the time of sepsis diagnosis.
Term Genes p-value (FDR)
Response to wounding GO:0009611 TNF*, HPS6, CXCL3, CCR1, CXCL2, CLU, TLR2, TLR4, CCL4, IGSF10, DYSF,
CCL3L3, IL1B, NFKBIZ, CR1, IL8, PLEK, SOD2, S100A12, CD55, F5, ADM,
STAB1, RIPK2, PTAFR
9.48E-09
Inflammatory response GO:0006954 NFKBIZ, CR1, TNF, IL8, CCR1, CXCL3, CLU, CXCL2, TLR2, TLR4, CCL4,
S100A12, CD55, STAB1, CCL3L3, RIPK2, IL1B, PTAFR
1.91E-06
Defense response GO:0006952 NFKBIZ, CR1, TNF, KLRC3, ADORA2B, IL8, RNASE3, CCR1, CXCL3, CLU,
CXCL2, CD160, TLR2, TLR4, CCL4, S100A12, GCH1, CD55, STAB1, CCL3L3,
RIPK2, IL1B, PTAFR
7.09E-06
Response to bacterium GO:0009617 TNF, RNASE3, TLR2, FASLG, TLR4, GCH1, S100A12, ADM, STAB1, RIPK2,
IL1B, PTAFR, MGST1
9.62E-04
Positive regulation of interleukin-6 production
GO:0032755
TNF, ADORA2B, TLR2, IL1B, RIPK2, TLR4 5.97E-04
Response to molecule of bacterial origin GO:0002237 ADM, TLR2, IL1B, RIPK2, FASLG, TLR4, MGST1, PTAFR, GCH1 8.23E-04
Immune response GO:0006955 ICAM1, CR1, TNF, AQP9, IL8, CCR1, CXCL3, CLU, CXCL2, TLR2, FASLG,
TLR4, CCL4, GCH1, CD55, CCL3L3, IL1B, CLEC4D, TREM1, PTAFR
0.005040035
Response to lipopolysaccharides GO:0032496 ADM, IL1B, RIPK2, FASLG, TLR4, MGST1, PTAFR, GCH1 0.00513737
Chemotaxis GO:0006935 RNASE2, IL8, CXCL3, CCR1, CXCL2, CCL3L3, IL1B, AMOT, CCL4, PTAFR 0.010807363
Regulation of interleukin-6 production GO:0032675 TNF, ADORA2B, TLR2, IL1B, RIPK2, TLR4 0.017318007
Positive regulation of NF-kB transcription
factor activity GO:0051092
ICAM1, TNF, TLR2, IL1B, RIPK2, TLR4 0.033317766
*Genes in bold: increased expression in septic patients than in healthy volunteers.
doi:10.1371/journal.pone.0091886.t002
Figure 2. Global gene expression and patient outcome.
Unsupervised classification by principal components analysis (PCA) of
septic patients considering the outcome. Two separate clusters depict
survivors and non-survivors, and this result is independent of the date
of sample collection. Numbers refers to patients’ identification and the
day of sample collection (0 or 7).
doi:10.1371/journal.pone.0091886.g002
Gene Expression and Outcomes from Septic Patients
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Gene expression profile in septic patients revealed differential
regulation compared to healthy volunteers. PCA clearly segregat-
ed patients and healthy volunteers. Interestingly, global gene
expression clustered P107 together with severe sepsis and P217
with septic shock, an indication that patient responses at early
stages of sepsis could be indicative of outcome.
The expression of genes involved in response to bacteria in
septic patients was noteworthy in our data (GO:0006952,
GO:0009617, GO:0002237 and GO:0032496). Among these
genes, we highlight the overexpression of TLR2 and TLR4 in
septic patients. These genes are implicated in the recognition of
bacterial cell wall components, such as lipopolysaccharide (LPS),
and play a key role in the host response to infection [18–20].
TRL2 and TLR4, together with ICAM1, TNF, IL1B and RIPK2,
are implicated in the positive regulation of nuclear factor-kB (NF-
kB) (GO:0051092). This transcription factor has been reported to
be critical for the expression of cytokines involved in inflammatory
diseases such as sepsis syndrome, albeit through complex
activation pathways [21]. Although NF-kB is not down-regulated
at the transcript level in the samples studied here, the gene
encoding NF-kB inhibitor zeta (NFKBIZ) is highly expressed in
samples from septic patients. [22]. The expression of IL8, TNF,
CXCL and IL1B in septic patients is implicated in the regulation
of several interconnected pathways. These mediators interact
within the NOD-Like receptor signaling pathway (http://www.
genome.jp/kegg/pathway/hsa/hsa04621.html) and also act to-
gether with TRL2 and TRL4, elements of the Toll-like receptor
signaling pathway (hsa04620:Toll-like receptor signaling pathway),
in response to bacterial infection. Additionally, they may interact
with CCR1, CCL3L3, and CCL4, elements of the Cytokine-
cytokine receptor interaction pathway (http://www.genome.jp/
kegg/pathway/hsa/hsa04060.html) that are similarly highly
expressed in patient samples.
In addition, chemotaxis-related genes were identified as
significantly dysregulated between the two groups
(GO:0006935). The expression of CXCL2 is noteworthy because
it is consistently up-regulated in early sepsis when compared to
healthy individuals, and polymorphisms in this gene have been
associated with outcomes in severe sepsis [23]. Chemotaxis is a
complex process that leads to cell migration to the site of infection.
This process involves endothelial activation by cytokines and the
production of chemokines. Additionally, chemotaxis depends on
the expression of chemokines receptors, L-selectins and integrins,
which are involved in the activation, rolling and adhesion of
leukocytes to endothelial cells, and in transmigration to the
infected tissue. The increased expression of chemotaxis-related
genes in mononuclear cells in samples collected at the time of
admission suggests that these cells are recruited to infectious/
inflammatory sites. This finding contrasts with functional studies
evaluating neutrophil chemotaxis during lethal cecal ligation and
puncture CLP sepsis. Reduced neutrophil migration to the site of
infection is associated with a worse prognosis during sepsis [24].
Moreover, CXCR2, a chemokine receptor involved in neutrophil
migration to sites of injury, was observed to be reduced on the
Table 3. Gene Ontology (GO) terms significantly represented among genes differentially expressed between D0 and D7 time
points for non-survivors.
Term Genes* p-value (FDR)
Inflammatory response GO:0006954 IL6, TNF, CCL2, OLR1, ADORA2A, KL, CFB, CCR1, CXCL3, CXCL2, IL1RN, NFKB1, CCL7,
CXCL10, TNFAIP6, SIGLEC1, IL23A, CCL23, SAA1, PTX3, IL1A
1.07E-08
Defense response GO:0006952 TNF, CCL2, ADORA2A, CXCL3, CCR1, CXCL2, NFKB1, CD74, CCL7, CXCL10, IL23A, CCL23,
SAA1, PTX3, IL1A, PLD1, IL6, OLR1, KL, CFB, IL1RN, TNFAIP6, SIGLEC1, IFNB1, CLEC5A
9.56E-07
Response to wounding GO:0009611 IL6, TNF, CCL2, OLR1, ADORA2A, KL, CFB, CCR1, CXCL3, CXCL2, IL1RN, NFKB1, CCL7,
CXCL10, SIGLEC1, TNFAIP6, IL23A, CCL23, FGA, SAA1, PDGFRA, PTX3, IL1A
1.77E-06
Immune response GO:0006955 CSF3, TNF, CCL2, CXCL3, CCR1, CXCL2, OAS3, IFI44L, CCL7, CD74, CXCL10, IL23A, CCL23,
PTX3, IL1A, IL6, OLR1, PTGER4, CFB, IL1RN, STXBP2, HLA-DQA2, OASL, TREM1, CLEC5A, GBP1
1.84E-06
Chemotaxis GO:0006935 CCRL2, PLD1, IL6, CCL23, CCL2, SAA1, CXCL3, CCR1, CXCL2, ITGA1, CCL7, CXCL10 2.59E-04
Cytokine-mediated signaling pathway
GO:0019221
CSF3, IL6, TNF, CCL2, CCR1, DUOX1, IL1A 5.56E-02
*All genes presented increased expression on D0 than on D7.
doi:10.1371/journal.pone.0091886.t003
Table 4. Gene Ontology (GO) terms significantly represented among genes differentially expressed between D7 samples for
survivors and non-survivors.
Term Genes* p-value (FDR)
Immune response GO:0006955 KYNU, NBN, HLA-DRB1, HLA-DRB3, TLR1, OAS3, CCL8, STXBP2, TLR4, CTSS, HLA-DMA,
HLA-DQA1, CD74, CD86, BPI, LILRA3, CLEC4A, LTF, CLEC7A, TREM1, CLEC5A, HLA-DRA
4.55E-06
Antigen processing and presentation of peptide or
polysaccharide antigen via MHC class II GO:0002504
HLA-DRB1, HLA-DRB3, HLA-DMA, CD74, HLA-DQA1, HLA-DRA 1.74E-05
Defense response GO:0006952 PLD1, KYNU, CAMP, TLR1, SOCS6, CCL8, TLR4, CD74, SIGLEC1, BPI, LILRA3, DEFA4, LTF,
CLEC7A, CLEC5A, HLA-DRA
1.21E-03
Cell activation GO:0001775 EGR1, NBN, CD86, PIK3CB, TLR1, STXBP2, TLR4, CLEC7A, HLA-DMA, CD74 2.34E-03
*All genes presented increased expression in survivors than in non-survivors.
doi:10.1371/journal.pone.0091886.t004
Gene Expression and Outcomes from Septic Patients
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surface of neutrophils from septic patients compared to healthy
volunteers in our cohort (unpublished data) and in previous works
[25,26]. It has been shown that mice subjected to CLP show
deficient neutrophil migration to the site of infection during severe
sepsis, which is associated with decreased expression of CXCR2
on the cell surface [27].
Genes involved in different aspects of oxidative phosphorylation
(http://www.genome.jp/kegg-bin/show_pathway?map00190) were
found to be modulated in septic patients. Their products are
components of mitochondrial electron transport chain (ETC) I–V.
Interestingly, the majority of these differentially expressed genes,
except for COX4I2 and COX6A2, were up-regulated in survivors
compared to non-survivors patients, suggesting an increased level of
mitochondrial dysfunction in the latter group.
In mitochondria, cellular energy in the form of ATP is produced
via oxidative phosphorylation. Mitochondria are the source and
targets of reactive oxygen species (ROS). In healthy cells, the
generation of ROS is tightly controlled, but in disease states
(including sepsis), ROS production is increased, causing tissue
damage [28]. Recent studies suggest that mitochondrial dysfunc-
tion induced by oxidative stress might be involved in sepsis-
mediated organ damage [29]. Additionally, an association
between mitochondrial dysfunction and sepsis outcomes has been
proposed [30].
There is increased ROS generation during experimental and
clinical sepsis. Plasma samples from patients with septic shock that
were co-cultured with human umbilical vein endothelial cells
induced ROS generation, an effect related to the severity of septic
shock [31]. We and others have reported increased ROS
generation by neutrophils from septic patients [32–34]. Increased
inducible nitric oxide synthase (iNOS) expression and NO
metabolites have also been observed during sepsis. We found that
monocytes and neutrophils from septic patients present increased
NO production [35]. In addition to their direct effects, NO and
superoxide (O22) spontaneously react to form the toxic peroxyni-
trite anion (ONOO2), which leads to cytotoxic and pro-
inflammatory responses [36]. Elevated levels of circulating
nitrotyrosine have been observed in patients with primary septic
shock, and concentrations are higher in non-surviving patients
compared to survivors [37,38].
ROS, NO and ONOO2 have a toxic impact on mitochondria
by inducing ETC dysfunction and apoptosis. The observed
decreased expression of genes belonging to ETC I–V in non-
survivors, which could reflect compromised mitochondrial respi-
ratory function, fits well with the known deleterious effects of the
oxygen and nitrogen reactive species in sepsis.
Dysfunctions in zinc homeostasis have also been implicated in
oxidative stress, and zinc reduces ROS via several mechanisms
[39]. Two zinc transporter families have been characterized: the
zinc transporter (ZnT)/solute carrier 30a (Slc30a) family and the
Zrt/Irt-like protein (ZIP)/solute carrier 39a (Slc39a) family [40].
Zinc concentration in plasma has been correlated with the
expression of zinc transporter genes as well as with patient
outcome following sepsis [41,42]. Although we do not present data
on zinc concentration, we did identify three members of the
SLC39A family that are down-regulated in non-survivors com-
pared to survivors at D0 (SLC39A6, SLC39A9 and SLC39A11).
This is coupled with broad dysregulation of several genes involved
in oxidative phosphorylation.
Neutrophils and monocytes are the primary cells of innate
immunity in host defense against infecting microorganisms. They
share a number of cell functions including phagocytosis and
intracellular killing of pathogens, production of cytokines and
generation of reactive oxygen species. Considering, however, the
specificities of each cell type, it would be interesting to evaluate if
the gene expression modulation observed in mononuclear cells in
our study has the same profile in neutrophils. In a previous work
evaluating the TLR signaling pathway in patients in different
stages of sepsis we found differences between PBMC and
neutrophils gene expression, with a trend of neutrophils to present
a broader up-regulation [20].
Patient’s samples were collected 7 days after admission allowing
us to analyze gene expression profile following sepsis progression
and therapeutic interventions.
PCA revealed that the patterns observed at admission persisted
on follow-up samples in survivors and non-survivors, indicating
that the host response to sepsis at the onset of the syndrome is
critical for patient outcome.
We found, however, that the gene ontology profiles in follow-up
samples (D0–D7) differed between survivors and non-survivors. In
non-survivors genes involved in immune response were down-
regulated on D7 compared to D0. Consistent with these results,
gene expression profiles in D7 samples from survivors differed
from non-survivors, with the immune system response more
intense in survivors. Notably, differences on D7 support a model in
which restoring the ability to induce adaptive immunity during
therapy is relevant for patient recovery.
As noted by Tang et al., sepsis elicits an inducible activation of
pathogen recognition receptors accompanied by an increase in the
activities of signal transduction cascades. Changes in inflammatory
responses are highly variable between studies, and there are
inconsistent changes in the expression of pivotal inflammatory/
anti-inflammatory cytokines, e.g. TNF-a, IL-1 and IL-10 [13]. In
part, this may reflect the timing of patient’s enrollment, since in a
previous work we found a dynamic modulation of ex-vivo
induction of TNF-a and IL-6 in whole blood of septic patients
related to the stages of sepsis [43].
In general we may consider that changes in gene expression in
our patients reflect a comprehensive host-response to infection and
the sustainability of their expression in follow-up samples is
associated with outcomes. In addition to the above described
induction of PRRs, the majority of up-regulated genes clustered
ontologically in host-defense pathways. While this profile might be
predicted for a patient fighting a potentially fatal infection, similar
trends have not been reported in other studies. Rather, genomic
studies have suggested that immune suppression predominates
during sepsis. One study evaluating whole genome gene expression
in mononuclear cells from patients with sepsis reported sepsis-
related immunosuppression and reduced inflammatory responses
[12]. However, this conclusion may overstate the role of the four
functional clusters that differ between septic and SIRS patients.
For example, a lymphocyte activation cluster was increased in
septic patients, while immune function and inflammatory response
clusters were increased in SIRS patients. In line with these results,
the same group has recently published an interesting paper using
whole blood from septic patients and healthy volunteers, in which
an ‘‘Immune Suppression Integer’’ is proposed in an attempt to
correlate gene dysregulation with clinical outcomes [44].
It is likely that the discrepancies between genomic studies
performed in clinical settings reflects differences of objectives,
inclusion criteria and approaches to evaluate gene expressions,
e.g., mononuclear cells vs. whole blood, as reviewed by Tang et al.
[13]. In fact, different studies may provide insight into different
aspects of the multi-complex host response during sepsis.
Multicenter studies with large numbers of patients might
contribute to more uniform results.
There are limitations to the present work. One of the most
important limitations is the sample size, which may have
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contributed to the exclusion of many sepsis-related changes in
gene expression from the final analysis. Nevertheless, our focus on
a single, community acquired infection identified significant
patterns that were sufficient to cluster patients and healthy
volunteers, as well as survivors and non-survivors. Genes that
were differentially expressed could be clustered accordingly to
gene ontology and pathway. Further, the time elapsed between
admission and follow-up samples did not allow observing changes
occurring in earlier days of intervention. Seven days interval is,
however, in consonance with earlier functional studies, which
revealed that blood cells from septic patients take several days to
restore their ex-vivo responses [45,46], and with a genomic study
in trauma patients showing that in patients with uncomplicated
recovery, gene expression tends to return to baseline within 7–
14 d for both up- and down-regulated genes, while in complicated
patients changes persisted longer period [47]. Finally, in this pilot
study, we did not confirm the results reported here with
quantitative PCR because we were interested in global patterns
and pathways of immune response rather than specific biomarkers.
Conclusions
Patients admitted with sepsis secondary to CAP exhibit a gene
induction profile when compared to healthy controls. Specifically,
genes clustered in host defense and inflammatory response
ontology were up-regulated during sepsis, consistent with the
needs for a host response to infection. Additionally, the patterns of
gene expression were able to cluster patients who survived from
those who succumbed to the infection. Comparisons of gene
expression from samples collected at the time of admission and in
follow-up samples identified differences between survivors and
non-survivors, with decreased expression of genes related to
immune functions in non-survivors. Further studies evaluating
other primary sources of sepsis are needed to evaluate if this is a
general gene expression profile or reflects a specific set of septic
patients.
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